

INDEVUS PHARMACEUTICALS INC  
Form 8-K  
March 10, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 10, 2009 (March 2, 2009)**

**Indevus Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction

of incorporation)

**000-18728**  
(Commission File Number)

**33 Hayden Avenue**

**Lexington, MA 02421-7966**

**04-3047911**  
(IRS Employer

Identification Number)

Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form 8-K

(Address of principal executive offices)

**Registrant's telephone number, including area code:**

**(781-861-8444)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 7.01. REGULATION FD DISCLOSURE.**

On March 2, 2009, Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) submitted an amendment to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for NEBIDO<sup>®</sup> (testosterone undecanoate) for the treatment of hypogonadism. The amendment has not yet been accepted by FDA for substantive review.

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Indevus Pharmaceuticals, Inc.

By: /s/ Michael W. Rogers

Name: Michael W. Rogers

Title: Chief Financial Officer

Dated: March 10, 2009